Tenax Therapeutics
TENX
5 hedge funds and large institutions have $1M invested in Tenax Therapeutics in 2013 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
1,726% more capital invested
Capital invested by funds: $55K → $1M (+$949K)
400% more funds holding
Funds holding: 1 → 5 (+4)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$135K |
| 2 |
EMG
Ellington Management Group
Old Greenwich,
Connecticut
|
+$135K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$135K |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$135K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAG
1
Private Advisor Group
Morristown,
New Jersey
| $493K | +$404K | +3 | New |
|
|
EMG
2
Ellington Management Group
Old Greenwich,
Connecticut
| $154K | +$135K | +1 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $79K | +$135K | +1 | New |
|
|
U
4
UBS
Zurich,
Switzerland
| $74K | +$135K | +1 | New |
|
5
Jane Street
New York
| $71K | – | – | – |
|
|
6
Barclays
London,
United Kingdom
| $67K | +$135K | +1 | New |
|
7
Morgan Stanley
New York
| $44K | – | – | – |
|
|
AIG
8
American International Group
New York
| $18K | – | – | – |
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
|
TDC
10
Thompson Davis & Co
Richmond,
Virginia
| $1K | – | – | – |
|
|
MPWT
11
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| $59 | – | – | – |
|
12
BNP Paribas Financial Markets
Paris,
France
| $36 | – | – | – |
|
|
SM
13
Sabby Management
Miami Beach,
Florida
| – | -$54K | -1 | Closed |
|
TENX Hedge Fund Activity: Q4 2013 in Review
5 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q4 2013, worth a combined $1M — up 1,726% from $55K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TENX positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Barclays, opening a new position worth an estimated $135K. The largest seller was Sabby Management, exiting entirely with an estimated $54K sold.
- 5 institutional investors held Tenax Therapeutics (TENX) as of Q4 2013, up from 1 in Q3 2013.
- Funds reported $1M of Tenax Therapeutics stock for Q4 2013, up 1,726% quarter-over-quarter.
- 5 funds opened new Tenax Therapeutics positions in Q4 2013 and 1 closed out, a net change of +4 holders.
- The largest Tenax Therapeutics buyer in Q4 2013 was Barclays, an estimated $135K added.
- The largest Tenax Therapeutics seller in Q4 2013 was Sabby Management, an estimated $54K sold.
Based on aggregated 13F filings for Q4 2013.